in-the-news-2

New Combination Chemotherapy Trials for Treating Infants with Leukaemia

Stage 3 trials of an experimental targeted cancer drug produced by AstraZeneca that includes a bacterial toxin shows promise in treating the most common cancer in children, B-cell acute lymphoblastic leukaemia (ALL). However, therapeutic benefits in the trial appear to be limited, because trial patients are quickly developing therapeutic resistance to the drug and relapse. A…